Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Income from Continuing Operations (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Income from Continuing Operations for 4 consecutive years, with 5051084.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 152.45% to 5051084.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 14739185.0, a 74.51% decrease, with the full-year FY2024 number at 9039831.0, down 13.89% from a year prior.
  • Income from Continuing Operations was 5051084.0 for Q3 2025 at bioAffinity Technologies, down from 4060787.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 88052.0 in Q2 2022 to a low of 5051084.0 in Q3 2025.
  • A 4-year average of 2460216.2 and a median of 2110279.0 in 2024 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 53.43% in 2023; the steepest drop was 1876.3% in 2023.
  • bioAffinity Technologies' Income from Continuing Operations stood at 1674583.0 in 2022, then plummeted by 41.72% to 2373164.0 in 2023, then dropped by 25.02% to 2966897.0 in 2024, then crashed by 70.25% to 5051084.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Income from Continuing Operations are 5051084.0 (Q3 2025), 4060787.0 (Q2 2025), and 2660417.0 (Q1 2025).